{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:47:20Z","timestamp":1778042840516,"version":"3.51.4"},"reference-count":43,"publisher":"Zhejiang University Press","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the Shandong Provincial Science and Technology Development Plan Project , China","award":["2013GSF11853"],"award-info":[{"award-number":["2013GSF11853"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Zhejiang Univ. Sci. B"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1631\/jzus.b1900089","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T08:05:08Z","timestamp":1575273908000},"page":"1003-1013","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A novel oncolytic adenovirus inhibits hepatocellular carcinoma growth","\u4e00\u79cd\u65b0\u7684\u6eb6\u7624\u817a\u75c5\u6bd2\u6291\u5236\u809d\u764c\u7ec6\u80de\u7684\u751f\u957f"],"prefix":"10.1631","volume":"20","author":[{"given":"Yu-huan","family":"Bai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-jing","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8153-3754","authenticated-orcid":false,"given":"Yan-jing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"635","published-online":{"date-parts":[[2019,12,2]]},"reference":[{"issue":"6","key":"389_CR1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3390\/cancers10060201","volume":"10","author":"AT Baker","year":"2018","unstructured":"Baker AT, Aguirre-Hern\u00e1ndez C, Halld\u00e9n G, et al., 2018. Designer oncolytic adenovirus: coming of age. Cancers 10(6): 201. https:\/\/doi.org\/10.3390\/cancers10060201","journal-title":"Cancers"},{"issue":"2","key":"389_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1478-3231.2011.02666.x","volume":"32","author":"MY Bao","year":"2012","unstructured":"Bao MY, Chen ZA, Xu YF, et al., 2012. Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P\/EDG1 axis in hepatocellular carcinoma. Liver Int 32(2): 331\u2013338. https:\/\/doi.org\/10.1111\/j.1478-3231.2011.02666.x","journal-title":"Liver Int"},{"issue":"10","key":"389_CR3","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.3390\/ijms18102109","volume":"18","author":"YH Bao","year":"2017","unstructured":"Bao YH, Guo YC, Zhang CL, et al., 2017. Sphingosine kinase 1 and sphingosine-1-phosphate signaling in colorectal cancer. Int J Mol Sci 18(10): 2109. https:\/\/doi.org\/10.3390\/ijms18102109","journal-title":"Int J Mol Sci"},{"issue":"1","key":"389_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.canlet.2011.03.021","volume":"307","author":"W Chen","year":"2011","unstructured":"Chen W, Wu YQ, Liu W, et al., 2011. Enhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinoma. Cancer Lett 307(1): 93\u2013103. https:\/\/doi.org\/10.1016\/j.canlet.2011.03.021","journal-title":"Cancer Lett"},{"issue":"8","key":"389_CR5","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.addr.2011.12.011","volume":"64","author":"JW Choi","year":"2012","unstructured":"Choi JW, Lee JS, Kim SW, et al., 2012. Evolution of oncolytic adenovirus for cancer treatment. Adv Drug Deliv Rev 64(8): 720\u2013729. https:\/\/doi.org\/10.1016\/j.addr.2011.12.011","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"389_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/CAD.0b013e328011334d","volume":"18","author":"O Cuvillier","year":"2007","unstructured":"Cuvillier O, 2007. Sphingosine kinase-1\u2014a potential therapeutic target in cancer. Anti-Cancer Drugs 18(2): 105\u2013110. https:\/\/doi.org\/10.1097\/CAD.0b013e328011334d","journal-title":"Anti-Cancer Drugs"},{"issue":"8","key":"389_CR7","doi-asserted-by":"publisher","first-page":"662","DOI":"10.2174\/138945008785132402","volume":"9","author":"SD Dai","year":"2008","unstructured":"Dai SD, Takabe K, Kapitonov D, et al., 2008. Targeting SphK1 as a new strategy against cancer. Curr Drug Targets 9(8): 662\u2013673. https:\/\/doi.org\/10.2174\/138945008785132402","journal-title":"Curr Drug Targets"},{"issue":"15","key":"389_CR8","doi-asserted-by":"publisher","first-page":"5920","DOI":"10.18632\/oncotarget.1874","volume":"5","author":"A Datta","year":"2014","unstructured":"Datta A, Loo SY, Huang BH, et al., 2014. SPHK1 regulates proliferation and survival responses in triple-negative breast cancer. Oncotarget 5(15): 5920\u20135933. https:\/\/doi.org\/10.18632\/oncotarget.1874","journal-title":"Oncotarget"},{"issue":"5","key":"389_CR9","doi-asserted-by":"publisher","first-page":"6277","DOI":"10.3892\/ol.2017.6938","volume":"14","author":"M Dong","year":"2017","unstructured":"Dong M, Chen ZH, Li X, et al., 2017. Serum Golgi protein 73 is a prognostic rather than diagnostic marker in hepatocellular carcinoma. Oncol Lett 14(5): 6277\u20136284. https:\/\/doi.org\/10.3892\/ol.2017.6938","journal-title":"Oncol Lett"},{"issue":"1","key":"389_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ijpharm.2016.08.036","volume":"512","author":"T Fang","year":"2016","unstructured":"Fang T, Dong YH, Zhang XM, et al., 2016. Integrating a novel SN38 prodrug into the PEGylated liposomal system as a robust platform for efficient cancer therapy in solid tumors. Int J Pharm 512(1): 39\u201348. https:\/\/doi.org\/10.1016\/j.ijpharm.2016.08.036","journal-title":"Int J Pharm"},{"issue":"11","key":"389_CR11","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1210\/me.2011-1048","volume":"25","author":"HY Guan","year":"2011","unstructured":"Guan HY, Liu LH, Cai JC, et al., 2011. Sphingosine kinase 1 is overexpressed and promotes proliferation in human thyroid cancer. Mol Endocrinol 25(11): 1858\u20131866. https:\/\/doi.org\/10.1210\/me.2011-1048","journal-title":"Mol Endocrinol"},{"issue":"4","key":"389_CR12","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00432-011-1138-2","volume":"138","author":"GQ He","year":"2012","unstructured":"He GQ, Lei W, Wang SB, et al., 2012. Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth. J Cancer Res Clin Oncol 138(4): 657\u2013670. https:\/\/doi.org\/10.1007\/s00432-011-1138-2","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"389_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4254\/wjh.v7.i1.101","volume":"7","author":"MA Kalogeridi","year":"2015","unstructured":"Kalogeridi MA, Zygogianni A, Kyrgias G, et al., 2015. Role of radiotherapy in the management of hepatocellular carcinoma: a systematic review. World J Hepatol 7(1): 101\u2013112. https:\/\/doi.org\/10.4254\/wjh.v7.i1.101","journal-title":"World J Hepatol"},{"issue":"2","key":"389_CR14","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1096\/fj.05-4331fje","volume":"20","author":"T Kawamori","year":"2006","unstructured":"Kawamori T, Osta W, Johnson KR, et al., 2006. Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J 20(2): 386\u2013388. https:\/\/doi.org\/10.1096\/fj.05-4331fje","journal-title":"FASEB J"},{"issue":"6","key":"389_CR15","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1172\/JCI9180","volume":"106","author":"T Kurihara","year":"2000","unstructured":"Kurihara T, Brough DE, Kovesdi I, et al., 2000. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 106(6): 763\u2013771. https:\/\/doi.org\/10.1172\/JCI9180","journal-title":"J Clin Invest"},{"issue":"24","key":"389_CR16","doi-asserted-by":"publisher","first-page":"6071","DOI":"10.1158\/1078-0432.CCR-10-0664","volume":"16","author":"OJ Kwon","year":"2010","unstructured":"Kwon OJ, Kim PH, Huyn S, et al., 2010. A hypoxia- and \u03b1-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas. Clin Cancer Res 16(24): 6071\u20136082. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-0664","journal-title":"Clin Cancer Res"},{"key":"389_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.critrevonc.2016.06.007","volume":"105","author":"A Lamarca","year":"2016","unstructured":"Lamarca A, Mendiola M, Barriuso J, 2016. Hepatocellular carcinoma: exploring the impact of ethnicity on molecular biology. Crit Revin Oncol\/Hematol 105: 65\u201372. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.06.007","journal-title":"Crit Revin Oncol\/Hematol"},{"issue":"24","key":"389_CR18","doi-asserted-by":"publisher","first-page":"19976","DOI":"10.18632\/oncotarget.5116","volume":"6","author":"C Larson","year":"2015","unstructured":"Larson C, Oronsky B, Scicinski J, et al., 2015. Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget 6(24): 19976\u201319989. https:\/\/doi.org\/10.18632\/oncotarget.5116","journal-title":"Oncotarget"},{"key":"389_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.lfs.2016.02.098","volume":"151","author":"H Liu","year":"2016","unstructured":"Liu H, Zhang CX, Ma Y, et al., 2016. SphK1 inhibitor SKI II inhibits the proliferation of human hepatoma HepG2 cells via the Wnt5a\/\u03b2-catenin signaling pathway. Life Sci 151: 23\u201329. https:\/\/doi.org\/10.1016\/j.lfs.2016.02.098","journal-title":"Life Sci"},{"issue":"1\u20132","key":"389_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jviromet.2009.07.011","volume":"162","author":"HY Liu","year":"2009","unstructured":"Liu HY, Han BJ, Zhong YX, et al., 2009. A three-plasmid system for construction of armed oncolytic adenovirus. J Virol Methods 162(1\u20132): 8\u201313. https:\/\/doi.org\/10.1016\/j.jviromet.2009.07.011","journal-title":"J Virol Methods"},{"issue":"16","key":"389_CR21","doi-asserted-by":"publisher","first-page":"21404","DOI":"10.18632\/oncotarget.7271","volume":"7","author":"YM Liu","year":"2016","unstructured":"Liu YM, Zhang XD, Sun T, et al., 2016. Knockdown of Golgi phosphoprotein 2 inhibits hepatocellular carcinoma cell proliferation and motility. Oncotarget 7(16): 21404\u201321415. https:\/\/doi.org\/10.18632\/oncotarget.7271","journal-title":"Oncotarget"},{"issue":"4","key":"389_CR22","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, 2001. Analysis of relative gene expression data using real-time quantitative PCR and the $${2^{ - {\\rm{\\Delta \\Delta }}{C_{\\rm{T}}}}}$$ method. Methods 25(4): 402\u2013408. https:\/\/doi.org\/10.1006\/meth.2001.1262","journal-title":"Methods"},{"key":"389_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3389\/fonc.2014.00145","volume":"4","author":"A Nguyen","year":"2014","unstructured":"Nguyen A, Ho L, Wan Y, 2014. Chemotherapy and oncolytic virotherapy: advanced tactics in the war against cancer. Front Oncol 4: 145. https:\/\/doi.org\/10.3389\/fonc.2014.00145","journal-title":"Front Oncol"},{"issue":"1","key":"389_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/1479-5876-9-157","volume":"9","author":"J Pan","year":"2011","unstructured":"Pan J, Tao YF, Zhou Z, et al., 2011. An novel role of sphingosine kinase-1 (SPHK1) in the invasion and metastasis of esophageal carcinoma. J Transl Med 9(1): 157. https:\/\/doi.org\/10.1186\/1479-5876-9-157","journal-title":"J Transl Med"},{"issue":"3","key":"389_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.14218\/JCTH.2017.00002","volume":"5","author":"E Rinninella","year":"2017","unstructured":"Rinninella E, Cerrito L, Spinelli I, et al., 2017. Chemotherapy for hepatocellular carcinoma: current evidence and future perspectives. J Clin Transl Hepatol 5(3): 235\u2013248. https:\/\/doi.org\/10.14218\/JCTH.2017.00002","journal-title":"J Clin Transl Hepatol"},{"issue":"3","key":"389_CR26","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/ajg.2012.449","volume":"108","author":"AG Singal","year":"2013","unstructured":"Singal AG, Nehra M, Adams-Huet B, et al., 2013. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol 108(3): 425\u2013432. https:\/\/doi.org\/10.1038\/ajg.2012.449","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"389_CR27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ymthe.2006.02.011","volume":"14","author":"EJ Small","year":"2006","unstructured":"Small EJ, Carducci MA, Burke JM, et al., 2006. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 14(1): 107\u2013117. https:\/\/doi.org\/10.1016\/j.ymthe.2006.02.011","journal-title":"Mol Ther"},{"issue":"15","key":"389_CR28","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.7150\/thno.20028","volume":"7","author":"HX Wang","year":"2017","unstructured":"Wang HX, Chen JM, Xu C, et al., 2017a. Cancer nanomedicines stabilized by \u03a0-\u03a0 stacking between heterodimeric prodrugs enable exceptionally high drug loading capacity and safer delivery of drug combinations. Theranostics 7(15): 3638\u20133652. https:\/\/doi.org\/10.7150\/thno.20028","journal-title":"Theranostics"},{"issue":"24","key":"389_CR29","doi-asserted-by":"publisher","first-page":"6963","DOI":"10.1158\/0008-5472.CAN-17-0984","volume":"77","author":"HX Wang","year":"2017","unstructured":"Wang HX, Lu ZJ, Wang LJ, et al., 2017b. New generation nanomedicines constructed from self-assembling small-molecule prodrugs alleviate cancer drug toxicity. Cancer Res 77(24): 6963\u20136974. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0984","journal-title":"Cancer Res"},{"issue":"14","key":"389_CR30","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.7150\/thno.26161","volume":"8","author":"HX Wang","year":"2018","unstructured":"Wang HX, Zhou LQ, Xie K, et al., 2018. Polylactide-tethered prodrugs in polymeric nanoparticles as reliable nano-medicines for the efficient eradication of patient-derived hepatocellular carcinoma. Theranostics 8(14): 3949\u20133963. https:\/\/doi.org\/10.7150\/thno.26161","journal-title":"Theranostics"},{"issue":"7","key":"389_CR31","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1631\/jzus.B1700156","volume":"19","author":"LY Wang","year":"2018","unstructured":"Wang LY, Zheng SS, 2018. Advances in predicting the prognosis of hepatocellular carcinoma recipients after liver transplantation. J Zhejiang Univ-Sci B (Biomed & Biotechnol) 19(7): 497\u2013504. https:\/\/doi.org\/10.1631\/jzus.B1700156","journal-title":"J Zhejiang Univ-Sci B (Biomed & Biotechnol)"},{"issue":"15","key":"389_CR32","doi-asserted-by":"publisher","first-page":"13564","DOI":"10.18632\/oncotarget.3769","volume":"6","author":"YG Wang","year":"2015","unstructured":"Wang YG, Liu T, Huang PP, et al., 2015. A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma. Oncotarget 6(15): 13564\u201313578. https:\/\/doi.org\/10.18632\/oncotarget.3769","journal-title":"Oncotarget"},{"issue":"1","key":"389_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1631\/jzus.B1600205","volume":"18","author":"ZD Wang","year":"2017","unstructured":"Wang ZD, Qu FY, Chen YY, et al., 2017. Involvement of microRNA-718, a new regulator of EGR3, in regulation of malignant phenotype of HCC cells. J Zhejiang Univ-Sci B (Biomed & Biotechnol) 18(1): 27\u201336. https:\/\/doi.org\/10.1631\/jzus.B1600205","journal-title":"J Zhejiang Univ-Sci B (Biomed & Biotechnol)"},{"issue":"9","key":"389_CR34","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.2174\/138920112800958751","volume":"13","author":"J Wong","year":"2012","unstructured":"Wong J, Lee C, Zhang K, et al., 2012. Targeted oncolytic herpes simplex viruses for aggressive cancers. Curr Pharm Biotechnol 13(9): 1786\u20131794. https:\/\/doi.org\/10.2174\/138920112800958751","journal-title":"Curr Pharm Biotechnol"},{"issue":"32","key":"389_CR35","doi-asserted-by":"publisher","first-page":"5601","DOI":"10.1039\/C5CC10367C","volume":"52","author":"HY Xie","year":"2016","unstructured":"Xie HY, Xu X, Chen JM, et al., 2016. Rational design of multifunctional small-molecule prodrugs for simultaneous suppression of cancer cell growth and metastasis in vitro and in vivo. Chem Commun (Camb) 52(32): 5601\u20135604. https:\/\/doi.org\/10.1039\/C5CC10367C","journal-title":"Chem Commun (Camb)"},{"issue":"4","key":"389_CR36","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1021\/acsami.7b14496","volume":"10","author":"L Xu","year":"2018","unstructured":"Xu L, Xu SJ, Wang HX, et al., 2018. Enhancing the efficacy and safety of doxorubicin against hepatocellular carcinoma through a modular assembly approach: the combination of polymeric prodrug design, nanoparticle encapsulation, and cancer cell-specific drug targeting. ACS Appl Mater Interfaces 10(4): 3229\u20133240. https:\/\/doi.org\/10.1021\/acsami.7b14496","journal-title":"ACS Appl Mater Interfaces"},{"issue":"3","key":"389_CR37","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.18632\/oncotarget.6564","volume":"7","author":"YZ Xu","year":"2016","unstructured":"Xu YZ, Dong BJ, Huang JW, et al., 2016. Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression. Oncotarget 7(3): 3233\u20133244. https:\/\/doi.org\/10.18632\/oncotarget.6564","journal-title":"Oncotarget"},{"issue":"4","key":"389_CR38","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3892\/etm.2015.2231","volume":"9","author":"J Yang","year":"2015","unstructured":"Yang J, Li JJ, Dai WQ, et al., 2015. Golgi protein 73 as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. Exp Ther Med 9(4): 1413\u20131420. https:\/\/doi.org\/10.3892\/etm.2015.2231","journal-title":"Exp Ther Med"},{"issue":"11","key":"389_CR39","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3779\/j.issn.1009-3419.2014.11.01","volume":"17","author":"L Yang","year":"2014","unstructured":"Yang L, Hu HL, Deng Y, et al., 2014. Role of SPHK1 regulates multi-drug resistance of small cell lung cancer and its clinical significance. Chin J Lung Cancer 17(11): 769\u2013777 (in Chinese). https:\/\/doi.org\/10.3779\/j.issn.1009-3419.2014.11.01","journal-title":"Chin J Lung Cancer"},{"issue":"13","key":"389_CR40","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.7314\/APJCP.2015.16.13.5541","volume":"16","author":"XD Yang","year":"2015","unstructured":"Yang XD, Pan LH, Wang L, et al., 2015. Systematic review of single large and\/or multinodular hepatocellular carcinoma: surgical resection improves survival. Asian Pac J Cancer Prev 16(13): 5541\u20135547. https:\/\/doi.org\/10.7314\/APJCP.2015.16.13.5541","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"389_CR41","first-page":"204","volume":"49","author":"CX Zhang","year":"2014","unstructured":"Zhang CX, Liu H, Gong YY, et al., 2014. Inhibitions of SphK1 inhibitor SKI II on cell cycle progression and cell invasion of hepatoma HepG2 cells. Acta Pharm Sin 49(2): 204\u2013208 (in Chinese).","journal-title":"Acta Pharm Sin"},{"key":"389_CR42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2407-12-17","volume":"12","author":"Y Zhou","year":"2012","unstructured":"Zhou Y, Yin X, Ying J, et al., 2012. Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. BMC Cancer 12: 17. https:\/\/doi.org\/10.1186\/1471-2407-12-17","journal-title":"BMC Cancer"},{"issue":"3","key":"389_CR43","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.3892\/or.2014.3683","volume":"33","author":"LM Zhu","year":"2015","unstructured":"Zhu LM, Wang Z, Lin YX, et al., 2015. Sphingosine kinase 1 enhances the invasion and migration of non-small cell lung cancer cells via the AKT pathway. Oncol Rep 33(3): 1257\u20131263. https:\/\/doi.org\/10.3892\/or.2014.3683","journal-title":"Oncol Rep"}],"container-title":["Journal of Zhejiang University-SCIENCE B"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B1900089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1631\/jzus.B1900089\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B1900089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T19:09:57Z","timestamp":1606763397000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1631\/jzus.B1900089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["389"],"URL":"https:\/\/doi.org\/10.1631\/jzus.b1900089","relation":{},"ISSN":["1673-1581","1862-1783"],"issn-type":[{"value":"1673-1581","type":"print"},{"value":"1862-1783","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"23 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yu-huan BAI, Xiao-jing YUN, Yan XUE, Ting ZHOU, Xin SUN, and Yan-jing GAO declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}},{"value":"The use and care of experimental animals were approved by the Institutional Animal Care and Use Committee, Qilu Hospital of Shandong University (Shandong, China).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}}]}}